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Abstract We report that sodium butyrate, a natural product of
fiber degradation by colonic bacteria, markedly suppresses
c-Myc-mediated apoptosis induced in murine plasmacytomas
and human Burkitt lymphomas by growth factor deprivation, but
not in cell lines devoid of c-myc translocations. Attenuation of
cell death is associated with downregulation of the rearranged
c-myc and activation of pRb via its dephosphorylation. We
suggest that in vivo sodium butyrate may play an important role
in plasmacytomagenesis by supporting the survival of cells with
c-myc translocations, which otherwise would be eliminated by the
lack of growth factors.
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1. Introduction
Millimolar concentrations of sodium butyrate are produced
in the large bowel of most vertebrates by colonic bacteria. It
regulates the in vivo growth and maturation of colonic epi-
thelial cells by promoting their di¡erentiation and, eventually,
their apoptosis, which is a part of their normal life cycle. It
also induces growth arrest, di¡erentiation and apoptosis in a
number of colon and myeloid tumor cell lines. The latter is
thought to be a molecular mechanism that could account for
the correlation between a high-¢ber diet and low incidence of
colorectal cancer and gives a rationale for a trial of sodium
butyrate as a ‘di¡erentiating’ antineoplastic drug [1]. The cell
cycle e¡ects of butyrate are probably a consequence of its
ability to a¡ect the expression of various genes, including
the cell cycle-related c-fos, cdc2, p53 and c-myc (both normal
and rearranged) [2^5]. The ability of sodium butyrate to in-
duce expression of the fetal hemoglobin gene has attracted
attention as a potential treatment of sickle cell disease and
thalassemia [6]. Association of normal fetal hemoglobin with
the mutant protein increases survival of erythrocytes up to
20% compared to 4^8% in untreated cells. High (millimolar)
concentrations of sodium butyrate that are suggested for
treatment of colon cancer and thalassemia are rapidly metab-
olized in vivo and reach micromolar concentrations in plasma
after 9^10 h [1].
The ability of sodium butyrate to decrease transcription of
rearranged c-myc has attracted our attention in connection to
recent studies of Myc-dependent apoptosis, which demon-
strated that in the absence of growth factors the cells with
deregulated c-myc expression are unable to shut it down
and to arrest their cell cycle progression [7]. These cells under-
go Myc-mediated apoptosis upon entry into the S phase of
cell cycle (or later in the cell cycle). In fact, in myeloid cells [8],
¢broblasts [9], EBV-transfected B lymphocytes [10], and Bur-
kitt lymphoma cells [11] that constitutively express c-Myc, the
apoptosis triggered by growth factor withdrawal is critically
dependent on the presence of this protein. In these cells, apop-
tosis can be abrogated by downregulation of c-Myc with anti-
sense oligonucleotides or inactivation of ectopically expressed
chimeric c-Myc protein. c-Myc-mediated apoptosis may pro-
tect an organism from expansion of naturally occurring cells
with deregulated c-myc generated as a result of tumorigenic
chromosomal translocations that place c-myc under the con-
trol of immunoglobulin enhancers, e.g. human Burkitt lym-
phomas and murine plasmacytomas [12]. We suggest that a
decrease of c-myc expression by sodium butyrate in certain
circumstances might reduce apoptosis in cells carrying c-myc
translocations and increase their chances for survival and fur-
ther malignization. To test this hypothesis we have studied the
e¡ect of sodium butyrate on apoptotic cell death in murine
and human B cell tumors ^ plasmacytomas and Burkitt lym-
phomas.
2. Materials and methods
2.1. Cell culture
Interleukin-6 (IL-6)-dependent murine T1165 and T1198 plasmacy-
toma cell lines [13] were maintained in RPMI 1640 medium (Whit-
aker/MA Bioproducts), supplemented with 10% heat-inactivated fetal
calf serum, 50 mM 2-mercaptoethanol, 50 mg/ml gentamicin and 100
plasmacytoma growth factor units/ml of recombinant murine IL-6.
Burkitt lymphoma cell lines JD38 and Daudi (American Type Culture
Collection) were maintained on the same medium, but without 2-
mercaptoethanol and IL-6. IL-3-dependent murine pre-B cell line
Baf3 was grown on the same medium with 5% of WEHI-3 super-
natant as a source of murine IL-3. IL-2-dependent murine cell lines
CTLL-2 and 279 were maintained on the same medium with 10 units/
ml of recombinant IL-2. To deprive cells from growth factors, they
were centrifuged at 180Ug and washed three times with growth fac-
tor-free or serum-free (for Burkitt lymphoma cells) medium. For stud-
ies of proliferation and apoptosis, cells were seeded at a concentration
of 2U105/ml in the same medium.
Treatment of plasmacytoma and Burkitt lymphoma cells with the
di¡erent concentrations of sodium butyrate was initiated immediately
after withdrawal of growth factors. Cell proliferation in the presence
of growth factors was assessed by the MTT assay 48 h after the
initiation of experiment. In the absence of growth factors viability
was determined 24 (for T1165) and 48 h (for T1198 and Burkitt
lymphomas) after the beginning of experiment. Experiments were re-
peated independently at least three times; each one was run in tripli-
cate. Average numbers and standard errors are shown on the ¢gures.
The MTT assay was performed as described in [13]. In a separate
series of experiments, we determined that measurements of viability
obtained with direct cell counts and MTT assay paralleled each other
in the presence and absence of growth factors.
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2.2. DNA extraction and analysis
5U106 cells were lysed for 4 h at 37‡C in 400 ml of lysis bu¡er (200
mM Tris-HCl, pH 7.6, 1 mM EDTA, 50 Wg/ml proteinase K and 1%
SDS) which was followed by 1 h treatment with 50 Wg/ml RNase A.
After phenol-chloroform extraction and ethanol precipitation, DNA
was rehydrated in TE bu¡er (10 mM Tris-HCl, pH 7.6, 1 mM
EDTA). 10^30 Wg of DNA per lane were electrophoresed in 1.2%
agarose gels containing 1 Wg/ml of ethidium bromide.
2.3. Western blots
Western blot analysis was performed as described [13] with mod-
i¢cations. The following lysis bu¡ers were used for Western blot anal-
ysis: c-Myc detection: 50 mM Tris-HCl, pH 7.2, 0.1% SDS, 50 mM
dithiothreitol, 10 Wg/ml aprotinin, 0.5 mM phenylmethylsulfonyl £uo-
ride, 0.3 M NaCl; for detection of other proteins NaCl in the bu¡er
was reduced to 0.1 M. Western blots were probed with polyclonal
murine-speci¢c antibodies against c-Myc (UBI), monoclonal anti-hu-
man c-Myc (Oncogene Science; Ab-1), monoclonal anti-p53 (Onco-
gene Science; Ab-3), monoclonal anti-Rb (Pharmingen) and mono-
clonal anti-hsp70 (StressGene). Goat anti-rabbit or anti-mouse IgGs
conjugated with horseradish peroxidase (Life Technologies BRL, Inc)
were used as secondary antibodies. The immunoreactive bands were
visualized on X-ray ¢lm using a chemiluminescent substrate (Kirke-
gaard and Perry Lab).
3. Results
3.1. Apoptotic cell death is induced by growth factor
withdrawal in murine plasmacytoma and human Burkitt
lymphoma cell lines
We have studied the process of cell death in several cell
lines that carry c-myc chromosomal translocations, murine
plasmacytomas and human Burkitt lymphomas. As we re-
ported earlier, upon growth factor withdrawal the IL-6-de-
pendent murine plasmacytomas T1165 and T1198 undergo
apoptotic cell death with viability decreasing to 25% within
1 or 2 days, respectively. Cell death is accompanied by typical
apoptotic morphology and ladder-like DNA degradation [13].
Serum removal from Burkitt lymphoma cell lines JD38 and
Daudi results in apoptotic cell death within 2^3 days. Serum-
starved cells displayed the typical morphological features of
apoptosis as was shown by £uorescent microscopy of cells
stained with acridine orange. Cells lost volume, the plasma
membrane became ru¥ed, chromatin collapsed into crescents
along the nuclear envelope, the nucleus broke up into spheres
and ¢nally cells were fragmented into apoptotic bodies (Fig.
1A). DNA isolated from serum-deprived Burkitt lymphoma
cells had typical apoptotic ladders with fragments in multiples
of 180^200 bp in length, whereas cells maintained with serum
yielded intact high molecular weight DNA (Fig. 1B).
Thus, we have established that growth factor deprivation
causes a typical apoptotic cell death in plasmacytoma and
Burkitt lymphoma cell lines used in this work.
3.2. Sodium butyrate suppresses apoptosis in growth factor-
starved plasmacytoma and Burkitt lymphoma cells
Sodium butyrate was proposed for treatment of several dis-
orders by oral administration at millimolar concentrations
that are naturally present in the gut. However, sodium buty-
rate is metabolized very quickly and reaches only micromolar
concentrations in plasma a few hours after administration [1].
We have assessed the e¡ect of physiological concentrations
of sodium butyrate on cell proliferation and apoptotic death
induced in mouse plasmacytoma and human Burkitt lympho-
ma cells by deprivation of IL-6 and serum, respectively. The
highest non-toxic concentrations (250 WM for T1165 and
T1198 cells ; 2 mM for JD38 and Daudi cells) were used in
most experiments. They were determined for each cell line by
monitoring a number of dead cells in the presence of the
growth factor over a period of 3 days. In the presence of
growth factors sodium butyrate inhibited proliferation of all
cell lines in a concentration-dependent manner (Fig. 2). In the
absence of growth factors butyrate added for the whole time
of growth factor withdrawal signi¢cantly suppressed apopto-
sis, leading to an almost complete survival of cells at the times
when 50^70% of the control cells were dead (Fig. 3A). Attenu-
ation of the apoptotic cell death was also concentration-de-
pendent.
Prolonged treatment with sodium butyrate suppresses the
apoptotic cell death induced in T1165 by withdrawal of IL-6
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Fig. 1. Apoptotic cell death in Burkitt lymphoma JD38 cells induced by deprivation of serum for 62 h. A: Fluorescent microscopy of cells
stained with acridine orange. B: DNA degradation patterns induced in JD38 cells by incubation without serum for the indicated periods of
time.
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(Fig. 3A). Suppression of apoptosis in these cells induced by
addition of the drug for 9, 17 and 24 h, followed by wash out,
was proportional to the time of treatment (Fig. 3B). Addition
of sodium butyrate at 18 or 21 h after IL-6 withdrawal had no
e¡ect (not shown). We conclude that a prolonged (more than
10 h) treatment is necessary for apoptosis suppression. Tumor
cell lines that do not have rearranged c-myc gene and exhibit
Myc-independent apoptosis were used as control. The IL-3-
dependent murine pre-B cell line Baf3 rapidly downregulates
c-Myc after growth factor withdrawal and 1^2 days later
undergoes apoptosis which therefore is c-Myc-independent
[14]. The IL-2-dependent human T-cell lines CTLL-2 and
279 have a very low expression of c-myc (see below). They
undergo apoptosis within 2 days after growth factor depriva-
tion. In these cell lines sodium butyrate did not cause any
signi¢cant attenuation of apoptosis (Fig. 2).
We conclude that sodium butyrate suppresses apoptosis in
the cell lines with c-myc expression deregulated by chromoso-
mal translocation, but not in the cell lines with normal c-myc.
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Fig. 3. A: Viability of IL-6-deprived T1165 cells with and without
treatment by 250 WM sodium butyrate. Butyrate was added immedi-
ately after IL-6 withdrawal for the whole time of experiment. Live
and dead cells were counted at di¡erent time points using trypan
blue exclusion. B: IL-6-deprived T1165 cells were treated with 250
WM of sodium butyrate for the indicated periods of time. Then bu-
tyrate was washed out and cells were further incubated with IL-6-
free medium up to 24 h. Then cell viability was determined using
the MTT assay. The cell viability in the control sample, which was
re-supplied with IL-6 at 12 h after IL-6 withdrawal so that the cells
neither died nor proliferated extensively, was considered as 100%.
Fig. 2. E¡ect of non-toxic concentrations of sodium butyrate (A) on cell proliferation (in the presence of growth factors) and (B) on cell death
(in the absence of growth factors). Cell viability was determined by the MTT assay at the following times after growth factor withdrawal in
the presence or absence of butyrate: 24 h for T1165, Baf3 and CTLL-2, and 48 h for JD38, Daudi and T1198. At the time of measurement
cell cultures were also evaluated for the presence of apoptotic cells using acridine orange staining and trypan blue exclusion methods (data not
shown). Roughly two thirds of the cells were dead in growth factor-deprived samples not treated with butyrate, and no dead cells were present
in samples supplied with growth factors both treated and not treated with butyrate.
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3.3. Apoptosis suppression by sodium butyrate is associated
with downregulation of rearranged c-myc and activation
of pRb but there is no change in p53
The products of c-myc oncogene and of Rb and p53 tumor
suppressor genes are known to be the important regulators of
cell proliferation and apoptosis. We have checked if changes
in Rb and p53 proteins accompany apoptosis suppression by
butyrate in plasmacytoma and Burkitt lymphoma cells.
We found very little expression of p53 in T1165 plasmacy-
toma cells, and the level of its expression was not modulated
by sodium butyrate at concentrations that were e¡ective in
cell death suppression and c-Myc modulation (Fig. 4). How-
ever, mitomycin C treatment which brings up a p53-mediated
cell cycle arrest (not shown) signi¢cantly elevated p53 level in
this cell line.
In Burkitt lymphoma JD38 the level of c-Myc protein ¢rst
decreases upon serum deprivation and then comes up at 24^28
h, coinciding with the onset of apoptosis. The second peak of
c-Myc expression was almost completely abrogated by sodium
butyrate (Fig. 5). In IL-6-deprived T1165 cells the level of
c-Myc did not change appreciably for at least 18 h (Fig. 5
and not shown). Treatment with 250 WM sodium butyrate for
the entire period of IL-6 withdrawal decreased the level of
c-Myc protein 2^3 times by 16 h (Fig. 5). Exposure to sodium
butyrate for a shorter period of time had no signi¢cant e¡ect
on c-Myc expression. Thus, in both Burkitt lymphoma and
plasmacytoma cells the death suppression is accompanied by a
decrease of c-Myc expression and there is a temporal correla-
tion between these two e¡ects.
The two cell lines that exhibited Myc-independent apoptosis
were also examined for c-Myc content (not shown). In Baf3,
as reported previously [15], c-Myc dropped dramatically after
IL-3 withdrawal and remained unchanged until the onset of
cell death. IL-2-dependent CTLL-2 cells had very low level of
c-Myc, both in the presence and in the absence of the growth
factor, and it was not changed signi¢cantly by butyrate treat-
ment during the time preceding the onset of apoptosis.
The pRb tumor suppressor protein is regulated by its phos-
phorylation state [16]. Proteins of the pRb family have been
shown to be involved in the regulation of c-Myc expression
[17] and function [18,19] and in the control of apoptosis
[20,21]. Their phosphorylation status can be a¡ected by so-
dium butyrate [22,23]. We studied the regulation of pRb by
sodium butyrate using a mobility shift assay [22]. pRb nor-
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Fig. 5. The e¡ects of sodium butyrate on c-Myc and pRb proteins in growth factor-withdrawn T1165 (A) and JD38 (B) cells. Cells were incu-
bated in IL-6-free or serum-free medium, respectively, for the indicated periods of time, in the presence or absence of sodium butyrate. pRb,
c-Myc and Hsp70 proteins were analyzed by Western blots using antibodies developed against murine pRb (Pharmingen), human c-Myc (Onco-
gene Science, Ab-1), murine c-Myc (UBI) and Hsp70 (StressGene).
Fig. 4. The e¡ect of sodium butyrate treatment and/or IL-6 with-
drawal on p53 content in T1165 cells. The cells were incubated
without IL-6 for various periods of time with or without of 250 WM
of sodium butyrate. p53 content was analyzed by Western blot us-
ing monoclonal anti-p53 antibodies (Oncogene Science; Ab-3) and
Hsp70 monoclonal antibodies (StressGene), as a control, on lysates
prepared from the live cells puri¢ed on a Ficoll gradient. Cells
maintained on IL-6 and cells stimulated with 10 mg/ml mitomycin
C, which is known to induce an accumulation of p53, were included
as controls.
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mally appears on Western blots as a series of bands represent-
ing di¡erent phosphorylated forms. Slower moving forms are
hyperphosphorylated and inactive; faster moving forms are
hypophosphorylated and active in E2F binding and blocking
the cell cycle (reviewed in [16]). In the case of JD38 and T1165
cells we found dramatic changes in phosphorylation state of
Rb upon sodium butyrate treatment (Fig. 5). In both cases
pRb was converted to high-mobility hypophosphorylated ac-
tive forms. The conversion was temporally correlated with
c-Myc downregulation. Also, an increase of an overall level
of pRb was notable in butyrate-treated T1165 cells.
4. Discussion
Withdrawal of growth factors induces di¡erent changes in
cell biology, dependent on cell type. Some cell lines down-
regulate their immediate early genes (including c-myc), devel-
op G1/G0 arrest and undergo massive apoptosis in a short
time. Others can persist in this state dying slowly over a long
period of time. However, the massive apoptotic cell death can
be stimulated in these cells, if c-Myc protein is ectopically
expressed or deregulated in the process of oncogenic trans-
formation. Such ‘Myc-mediated’ apoptosis can be induced
in T-cell hybridomas [24], c-myc-transfected ¢broblasts
[15,25,26], EBV-immortalized B cells that have deregulated
c-myc [10], and B-cell tumors with c-myc deregulated by chro-
mosomal translocation [11]. In this study we found that so-
dium butyrate treatment, which promotes apoptosis in many
previously studied systems (reviewed in [1]), has very di¡erent
e¡ects on Myc-dependent versus Myc-independent cell death.
The latter is not signi¢cantly a¡ected (Baf3 cells) or enhanced
(CTLL-2) by sodium butyrate while the former is dramatically
suppressed. Death suppression is accompanied by c-Myc
downregulation and activation of pRb, a product of tumor
suppressor gene.
Interestingly, in plasmacytoma cell line T1165 we found
that modulation of p53 protein level is not involved in the
cell cycle block imposed by growth factor starvation [13] or in
butyrate-mediated death suppression. This adds to the body
of data which shows that Myc-mediated apoptosis may occur
in both p53-dependent and p53-independent ways [26,27].
However, as both pRb and p53 control arrest of cell cycle,
one may speculate that in our system the former mediates
apoptosis triggered by Myc, which would be consistent with
the evidence showing involvement of pRb in the control of
cell death in other systems [20,21].
It has been shown that downregulation of rearranged c-myc
by sodium butyrate is achieved through a block in c-myc
transcription [2], but its e¡ect on pRb phosphorylation has
not been investigated. It is tempting to speculate that pRb
may be regulated through Myc expression, which governs syn-
thesis of cyclins [28,29] and hence the activity of cdk/cyclin
kinases which phosphorylate pRb. On the other hand, the
proteins of the pRb family are able to interact with c-Myc
directly [18,19], which may provide another route for pRb-
Myc interplay.
As plasmacytoma tumors can be induced in BALB/c mice
experimentally, they have been studied in great detail (re-
viewed in [12]). Plasmacytomas can be induced by pristane
injections (priming) that cause a chronic in£ammation ^ oil
granuloma. They arise and proliferate in this environment
which provides a continuous source of IL-6, required for these
tumors at early stages of their development. Later plasmacy-
tomas lose their dependence on IL-6 and could proliferate in
mice independently of its presence or absence. As it was
shown recently, cells with c-myc translocations could be de-
tected in normal mice [30]. However, they do not proliferate
prior to pristane injection. This allows us to propose that
these cells, which apparently are IL-6-dependent and have
deregulated c-myc, would be eliminated by apoptosis unless
their survival is supported by naturally present sodium buty-
rate. Incidentally in non-primed mice the cells with transloca-
tions are found mostly in Peyer patches in the gut [30], where
sodium butyrate is present in high concentrations. Butyrate
may also play a role in supporting the cells leaving the place
where the translocation has occurred and increasing their
chances to ¢nd an ample supply of IL-6, proliferate and even-
tually progress to fully malignant, growth factor-independent
tumors. Given that (i) sodium butyrate suppresses apoptosis
in vitro, (ii) in many cases apoptosis suppression is known to
be a crucial part of tumorigenesis and (iii) butyrate is a phys-
iological substance and a proposed drug, we feel that inves-
tigation of its potential role in tumorigenesis in vivo is a
matter of high priority.
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